MDS stands for myelodysplastic syndromes, a group of blood cancers in which the bone marrow fails to produce enough healthy blood cells. In MDS, the stem cells inside your bone marrow don’t mature properly. Many of them die before they ever reach your bloodstream, leaving you short on red blood cells, white blood cells, platelets, or all three.
The term covers several related conditions rather than a single disease, which is why “syndromes” is plural. MDS primarily affects older adults, with a median age at diagnosis of 76 years, and roughly 86% of patients are over 60 when diagnosed.
How MDS Affects the Body
Your bone marrow is essentially a blood cell factory. It produces stem cells that are supposed to develop into mature red blood cells (which carry oxygen), white blood cells (which fight infection), and platelets (which help blood clot). In MDS, this production line breaks down. The stem cells grow abnormally, and at least 10% of cells in one or more of these cell lines show visible defects under a microscope. The result is a shortage of working blood cells circulating through your body.
That shortage drives the symptoms. Low red blood cells cause fatigue, shortness of breath, and unusual paleness. Low platelets lead to easy bruising, unexpected bleeding, and tiny red spots just beneath the skin called petechiae. Low white blood cells make you vulnerable to frequent infections. Many people have no symptoms early on, and MDS is sometimes discovered through routine blood work before any signs appear.
What Causes MDS
Most cases have no identifiable cause. These are called primary or “de novo” MDS. In some patients, MDS develops after previous cancer treatment with chemotherapy or radiation, which can damage bone marrow DNA over time. Ongoing exposure to certain industrial chemicals, particularly benzene, is another recognized risk factor.
At the genetic level, MDS involves acquired mutations and chromosomal abnormalities in bone marrow cells. These aren’t inherited in most cases. They accumulate with age, which helps explain why the disease overwhelmingly affects people in their 70s and beyond. The incidence climbs steeply with age, reaching as high as 75 per 100,000 people among those 65 and older.
How MDS Is Diagnosed
Diagnosis requires a combination of blood tests and a bone marrow biopsy. To qualify as MDS, a patient must have at least one type of blood cell count that falls below normal thresholds. The bone marrow sample is examined under a microscope to check for abnormal cell shapes and to count the percentage of immature cells called blasts.
The blast percentage is a critical number. In MDS, it ranges from 0% to 19%. Once blasts reach 20% or higher, the diagnosis shifts to acute myeloid leukemia (AML), a more aggressive blood cancer. Doctors record the exact blast percentage rather than a range, because even small differences affect treatment decisions and risk assessment.
MDS and Leukemia Risk
One of the most serious concerns with MDS is its potential to progress to AML. Historically, 30% to 40% of MDS patients eventually make this transition. However, the risk varies enormously depending on the subtype and severity of MDS.
A large study of over 1,900 patients initially classified as lower-risk MDS found that about 9% progressed directly to AML, while another 6.5% first worsened to higher-risk MDS before developing leukemia. In other words, lower-risk MDS carries a much smaller chance of transformation than the overall 30% to 40% figure suggests. Higher-risk subtypes account for the majority of progressions.
How Doctors Assess Risk
Not all MDS behaves the same way. Doctors use a scoring tool called the Revised International Prognostic Scoring System (IPSS-R) to estimate how a patient’s disease is likely to behave. It assigns points based on five factors: the types of chromosomal abnormalities present in bone marrow cells, the blast percentage, and the severity of each blood cell shortage (hemoglobin level, platelet count, and neutrophil count). Age is factored in as an additional consideration.
Chromosomal abnormalities carry the most weight. A normal chromosomal profile falls into the “good” category, while complex abnormalities involving more than three chromosomal changes are classified as “very poor.” The combined score places patients into risk categories ranging from very low to very high, which guides both prognosis and treatment planning.
Treatment Approaches
Treatment for MDS depends heavily on the risk category and the patient’s overall health. For lower-risk disease, the primary goal is managing symptoms and improving blood counts. This often means blood transfusions to address anemia and medications that stimulate the bone marrow to produce more cells. For many patients, especially those who are older or have other health conditions, this supportive approach offers the best balance of quality of life and survival.
For higher-risk MDS, treatment becomes more aggressive. Medications that target the abnormal DNA behavior in MDS cells are a standard option, working to help bone marrow cells mature more normally. Some patients receive chemotherapy regimens similar to those used for AML, though response rates are moderate, with roughly 40% of patients responding, and survival after treatment averaging around 10 to 11 months in studies of patients whose disease had already resisted initial therapy.
A stem cell transplant is the only treatment with the potential to cure MDS, but it carries significant risks and is only feasible for a small minority of patients. Most people with MDS are in their 70s and may have other health problems that make transplantation too dangerous. For patients who do undergo a transplant, three-year relapse-free survival has been reported at roughly 24% in studies of patients with advanced disease. Certain genetic mutations, particularly in the TP53 gene, are associated with shorter survival and earlier relapse even after transplant.
Other Meanings of MDS
Outside of medicine, MDS can refer to several other things. In dentistry, it stands for Master of Dental Surgery. In data management, it can mean Master Data Services, a feature in Microsoft’s SQL Server platform. In material safety contexts, MDS sometimes refers to Material Data Sheets. The medical meaning, myelodysplastic syndromes, is by far the most commonly searched definition.